Whitney Groth, NP
Family · Littleton, CONPI 1962648048
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,730 of the $11,178 with a category attached, or 60.2%. 36 manufacturers reported payments, led by Edwards Lifesciences at 52.2% of the total. 2025 is the largest year on record at $5,467, 6.5 times the $842 reported in 2021. Among family clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 228 payments — averaging $49.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$6K
- Impulse Dynamics (USA) Inc.$729
- Abiomed$587
- Amgen$479
- Shockwave Medical, Inc$435
- Boston Scientific$417
- plus $3K from 30 others
What the payments were for
- Consulting fees$3,00027%
- Travel & lodging$1,33412%
- Food & beverage$6,73060%
- Education$1141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 53 | $5,831 |
| Impulse Dynamics (USA) Inc. | 11 | $729 |
| Abiomed | 8 | $587 |
| Amgen | 23 | $479 |
| Shockwave Medical, Inc | 11 | $435 |
| Boston Scientific | 7 | $417 |
| AstraZeneca | 14 | $310 |
| Novartis | 9 | $300 |
| Boehringer Ingelheim | 12 | $261 |
| Abbott | 7 | $261 |
| E.r. Squibb & Sons, L.L.C. | 8 | $254 |
| Pfizer | 9 | $189 |
| Merck | 9 | $175 |
| Johnson & Johnson | 7 | $110 |
| Bayer | 6 | $100 |
| Novo Nordisk | 3 | $83 |
| Sanofi-aventis U.S. LLC | 3 | $71 |
| United Therapeutics Corporation | 2 | $57 |
| Scpharmaceuticals Inc. | 3 | $51 |
| Lilly USA, LLC | 3 | $49 |
| Heartflow, Inc. | 2 | $48 |
| Esperion Therapeutics, Inc. | 3 | $47 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $47 |
| Medtronic | 1 | $41 |
| ZOLL Respicardia, Inc. | 1 | $34 |
| Azurity Pharmaceuticals, Inc. | 1 | $30 |
| Amarin Pharma, Inc. | 1 | $24 |
| Biotronik Inc. | 1 | $22 |
| Cardiovascular Systems Inc. | 1 | $21 |
| Bridgebio Pharma, Inc. | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| Atricure, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,178 in reported general payments places this provider in the 95th percentile of 2,182 family providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 44 | $56,053 |
| JardianceEmpagliflozin | 46 | $51,528 |
| EntrestoSacubitril/Valsartan | 16 | $28,748 |
| XareltoRivaroxaban | 15 | $24,466 |
| Repatha SureclickEvolocumab | 31 | $22,095 |
| Metoprolol Succinate | 136 | $1,758 |
| Losartan Potassium | 109 | $810 |
| Rosuvastatin Calcium | 50 | $800 |
| Atorvastatin Calcium | 64 | $745 |
| Nebivolol Hcl | 13 | $716 |
| ClopidogrelClopidogrel Bisulfate | 43 | $609 |
| Carvedilol | 92 | $588 |
| Ezetimibe | 37 | $491 |
| Metoprolol Tartrate | 33 | $460 |
| Lisinopril | 70 | $384 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $189 | $56,05344 claims |
| Boehringer IngelheimJardiance | $261 | $51,52846 claims |
| NovartisEntresto | $300 | $28,74816 claims |
| Johnson & JohnsonXarelto | $110 | $24,46615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,182 family providers in Colorado.
Other family in Littleton
- Laurie BurnsLittleton$9K
- Corinne YoungColorado Springs$272K
- Margaret MachaffieColorado Springs$97K
- April RossGrand Junction$95K
- Jeannette LillerColorado Springs$74K
- Teal MeffordThornton$63K
- Jacquita JordanColorado Springs$52K
- Stephanie HanenbergColorado Springs$40K
- Courtney WeirFort Collins$30K
- Katie NadingDenver$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.